Inventera's Gadolinium-Free MRI Contrast Agent INV-002 Hits All Phase 3 Endpoints in MR Arthrography
核心洞察
Inventera (搜索) reported that its nano-based MRI contrast agent INV-002 met all primary efficacy endpoints in a Phase 3 trial of 85 patients requiring MR arthrography.
Independent central readers found statistically significant improvement in joint distension, contrast and sharpness versus non-contrast MRI across eight South Korean sites.
INV-002 uses biocompatible iron-based nanotechnology instead of gadolinium, which has been linked to nephrogenic systemic fibrosis (搜索) in patients with impaired kidney function.
Inventera (搜索) has received the final clinical study report for its nano-based magnetic resonance imaging contrast agent INV-002, confirming that the candidate met all primary efficacy endpoints in a Phase 3 trial conducted in South Korea. The company disclosed the results on September 21 and said it will now move the program into the regulatory filing and commercialization process.
Trial Design and Endpoints
The Phase 3 study enrolled 85 patients with known or suspected shoulder joint disorders (搜索) who required MR arthrography. It was conducted at eight institutions in Korea, including Seoul National University Bundang Hospital.
The trial was designed to determine how much MR arthrography using INV-002 improves image quality compared with MRI performed without a contrast agent. Independent central readers assessed three measures: joint distension, contrast and sharpness. All three showed statistically significant improvement after INV-002 was administered, which the company said means the trial met its primary efficacy objective.
Iron-Based Nanotechnology Instead of Gadolinium
INV-002 is a next-generation contrast agent that applies nanotechnology to biocompatible materials such as iron rather than gadolinium, the active ingredient in conventional MRI contrast agents. Gadolinium has raised concerns about nephrogenic systemic fibrosis (搜索), a serious adverse effect in patients with impaired kidney function. INV-002 is designed to avoid those safety issues while enhancing image quality and diagnostic accuracy, and is being developed for use in MR arthrography to diagnose musculoskeletal disorders.
No contrast agent is currently approved specifically for MR arthrography in the diagnosis of musculoskeletal conditions, so INV-002 could secure a first-mover position if authorized.
Regulatory Path and Commercialization Plans
With the final report in hand, Inventera (搜索) intends to file a new drug application for INV-002 with South Korea's Ministry of Food and Drug Safety (搜索). Chief Executive Shin Tae-hyun said the company plans to submit its marketing authorization application in the fourth quarter of this year.
"After obtaining approval, we expect meaningful revenue from INV-002 to begin next year, and we will use the commercialization of an in-house developed drug as a springboard to accelerate Inventera (搜索)'s growth," Shin said.
Inventera (搜索) noted that uncertainty remains over whether the investigational drug will ultimately win approval. Phase 3 success does not automatically translate into marketing authorization, and the ministry's review and approval decision will shape what happens next for the program.
Market Context
South Korea's contrast agent market is estimated at approximately 500 billion won, or about $360 million. X-ray and CT contrast agents account for roughly 440 billion won of that total, while MRI contrast agents represent about 66 billion won.
Business Research Insights projects the global contrast agent market will expand from 13.16 trillion won in 2022 to 17.42 trillion won in 2031, growing at a compound annual growth rate of 3.2%. If Inventera (搜索) secures approval, it would hold the first authorized product in the MR arthrography space, with potential to expand beyond South Korea into global markets. The MFDS review timeline and approval conditions remain pending, so further verification is needed before commercialization can begin.